LIXTE Biotechnology Holdings (NASDAQ: LIXT) has announced the filing of its first-quarter 2026 Form 10-Q, detailing continued advancement of its lead oncology candidate, LB-100. The company reported expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. This progress underscores LIXTE's commitment to developing novel cancer therapies and expanding its pipeline.
LB-100 is a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology known as activation lethality, which is advancing a new treatment paradigm. LIXTE's approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
In addition to its oncology pipeline, LIXTE highlighted continued growth at its recently acquired Liora Technologies Europe subsidiary. Liora Technologies is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Its proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. This strategic expansion strengthens LIXTE's capabilities in cancer treatment development and positions the company for broader market opportunities.
The company's progress in both its clinical pipeline and strategic initiatives reflects its focus on delivering innovative solutions for cancer patients. Investors can access the full press release and additional information on the company's newsroom at https://ibn.fm/LIXT. For more details about LIXTE Biotechnology Holdings, visit www.lixte.com. Information about Liora Technologies can be found at www.lioratechnologies.com.
The first-quarter filing provides investors with a clear view of LIXTE's operational achievements and strategic direction. With the advancement of LB-100 trials and the growth of Liora Technologies, LIXTE is positioning itself as a key player in both pharmaceutical and medical technology sectors. The company's focus on novel cancer targets and advanced treatment systems highlights the potential for meaningful contributions to oncology care.
